The approval is based on the results of Corcept’s Phase 3 ROSELLA trial, which showed improvements in both progression-free ...

Onco360 ®, the nation’s leading independent Specialty Pharmacy, has been selected as the national pharmacy partner by Corcept Therapeutics for LIFYORLI™ (relacorilant), which is indicated in ...

The FDA approved relacorilant (Lifyorli) in combination with nab-paclitaxel (Abraxane) for the treatment of adults with ...

Almost four months ahead of schedule, Corcept Therapeutics' selective glucocorticoid receptor antagonist (SGRA) relacorilant ...

Effect of nilotinib on cell proliferation and migration of ovarian cancer cells alone and in combination with standard chemotherapy. Background: Advances in laparoscopic surgery have allowed a ...